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We evaluated the prevalence of human bocavirus 
and KI and WU polyomaviruses in pediatric intensive care 
patients with and without lower respiratory tract infection 
(LRTI). The prevalence of these viruses was 5.1%, 0%, and 
2.6%, respectively, in children with LRTI and 4.8%, 4.8%, 
and 2.4%, respectively, in those without LRTI. 
T
hrough use of molecular diagnostic tests such as real-
time PCR in the clinical setting, our scope of etiologic 
viral agents of lower respiratory tract infection (LRTI) has 
increased. Respiratory viruses can now be detected in most 
pediatric intensive care patients with LRTI (1). Recently, 
3 new viruses were described: human bocavirus (HBoV) 
and KI (KIPyV) and WU (WUPyV) polyomaviruses (2–4). 
These viruses were ﬁ  rst identiﬁ  ed in respiratory samples 
obtained from children with respiratory tract infections. An 
association between the viruses and respiratory tract symp-
toms was postulated, but, to date, evidence supporting that 
association is incomplete (5–7). This study evaluates the 
prevalences of HBoV, KIPyV, and WUPyV infections in 
pediatric intensive care patients with acute respiratory in-
sufﬁ  ciency caused by LRTI.
The Study
Patients <5 years of age who were admitted for LRTI 
to the pediatric intensive care unit (PICU) of Wilhelmina 
Children’s Hospital, Utrecht, the Netherlands, were en-
rolled from October through May during 2005–2008. Pa-
tients were excluded if they had any of the following: asth-
ma exacerbation, immunocompromised state, indication 
for antimicrobial drugs other than for LRTI, and repeated 
PICU admission for LRTI during the study period. Control 
group participants were children <18 years of age (median 
2.2 years) who were admitted to the PICU from October 
2005 through March 2006 for reasons other than LRTI.
Clinical data were obtained by using standardized 
forms to extract data from electronic charts. Underlying ill-
nesses were deﬁ  ned as chronic pulmonary disease, congen-
ital heart disease, immunodeﬁ  ciency, malignancy, neuro-
logic disease, or gastrointestinal disease (8). To assess the 
severity of illness, we used the lowest ratio during the ﬁ  rst 
24 hours of the partial pressure of oxygen in arterial blood 
(PaO2) to the inspired oxygen fraction (FiO2). These ratios 
were acquired from the Pediatric Intensive Care Evalua-
tion database, which contains validated clinical data for all 
Dutch PICU admissions.
Nasopharyngeal aspirates were collected from all pa-
tients in the LRTI group as part of the investigation of their 
illnesses. In the control group, nasopharyngeal aspirates 
were taken from intubated patients, and throat swabs were 
taken from extubated children as part of routine surveil-
lance to identify transmission of respiratory syncytial virus 
(RSV). Because RSV surveillance was conducted as part 
of normal patient care, patient consent/ethical approval 
was not needed, according to the Medical Ethical Research 
Council of our institution.
Specimens from patients in the LRTI group were ini-
tially examined for RSV, inﬂ  uenza viruses, parainﬂ  uenza 
viruses, adenoviruses, rhinoviruses, coronaviruses, human 
metapneumovirus, and Mycoplasma pneumoniae by using 
real-time PCR as previously described (1,9,10). Specimens 
from patients in the control group were initially examined 
for RSV. All samples were retrospectively tested for HBoV, 
KIPyV, and WUPyV also by using real-time PCR as previ-
ously described (11,12). After nucleic acid extraction us-
ing the MagNA Pure LC 1.0 nucleic acid isolation system 
(Roche Diagnostics, Rotkreuz, Switzerland), ampliﬁ  cation 
was carried out in a 25-μL reaction mixture on a 7500 Fast 
Real-Time PCR System (Applied Biosystems, Foster City, 
CA, USA). Positive controls for the KIPyV and WUPyV 
PCR were provided by S. Bialasiewicz and T.P. Sloots, 
University of Queensland, Queensland, Australia, and the 
positive control for HBoV was provided by T. Allander, 
Karolinska Institute, Stockholm, Sweden. Internal con-
trol viruses were used to monitor efﬁ  cient extraction and 
ampliﬁ   cation. Real-time PCR results were expressed in 
cycle threshold (Ct) values. Ct values are inversely corre-
lated with viral load; i.e., low Ct values indicate high viral 
loads.
Of 90 LRTI patients enrolled, 78 (86.7%) had sufﬁ  -
cient material stored for HBoV, KIPyV, and WUPyV test-
ing. Eighty-eight control patients were enrolled, of which 
83 (94.3%) had sufﬁ  cient material stored to be included. 
Table 1 provides patients’ demographic and clinical char-
acteristics. The main clinical conditions of control patients 
were cardiac disease requiring surgery (33.7%), trauma 
DISPATCHES
454  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 3, March 2009
Author afﬁ  liations: University Medical Center Utrecht, Utrecht, the 
Netherlands (A.C. van de Pol, T.F.W. Wolfs, N.J.G. Jansen, J.L.L. 
Kimpen, A.M. van Loon, J.W.A Rossen); and St. Elisabeth Hospital 
Tilburg, Tilburg, the Netherlands (J.W.A. Rossen)
DOI: 10.3201/eid1503.081203Human Bocavirus and KI/WU Polyomaviruses
(8.4%), sepsis (8.4%), and upper respiratory tract infection 
(8.4%). A total of 57 (68.7%) nasopharyngeal aspirates and 
26 (31.3%) throat swabs from the 83 patients who had suf-
ﬁ  cient samples were tested.
In LRTI patients, HBoV was found in 4 (5.1%) and 
WUPyV in 2 (2.6%) of the 78 patients. No samples tested 
positive for KIPyV. Table 2 shows Ct values and clinical 
characteristics for LRTI patients whose samples were posi-
tive as well as for controls whose samples were positive 
for these viruses. Other respiratory viruses were found 
in 70 (89.7%) of the 78 children. RSV was found in 52 
(66.7%), inﬂ  uenza viruses in 3 (3.8%), parainﬂ  uenza vi-
ruses in 2 (2.6%), adenoviruses in 4 (5.1%), rhinoviruses 
in 20 (25.6%), coronaviruses in 6 (7.7%), human metap-
neumovirus in 5 (6.4%), and Mycoplasma pneumoniae in 
1 (1.3%) of the patients. Multiple respiratory viruses were 
found in 3 of the 4 LRTI patients with HBoV infection and 
in both patients with WuPyV infection (Table 2). One pa-
tient had a single infection with HBoV (i.e., no other virus 
was detected). This patient was born at 31 weeks of gesta-
tional age and had a history of a grade IV idiopathic respi-
ratory distress syndrome. She was admitted to the PICU at 
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Table 1. Demographic and clinical characteristics for PICU patients with LTRIs and for controls, the Netherlands, 2005–2008* 
Characteristics of patients   LRTI group, n = 78  Control group, n = 83 
Sex, no. (%) 
  M  43 (55.1)  44 (53.0) 
  F  35 (44.9)  39 (47.0) 
Nasopharyngeal aspirates, no. (%)  78 (100.0)  57 (68.7) 
Mechanical ventilation, no. (%)  76 (97.4)  79 (95.2) 
Age, mo, median (IQR)  1.5 (4.2)  26.1 (134) 
PaO2/FiO2, mm Hg, median (IQR)  130 (74.3)  250 (206) 
Time on ventilator, d, median (IQR)  9 (5)  4 (9) 
Time in hospital, d, median (IQR)  10 (6)  6 (11) 
*PICU, Pediatric Intensive Care Unit, Wilhelmina Children’s Hospital, Utrecht, the Netherlands; LRTI, lower respiratory tract infection; IQR, interquartile 
range; PaO2/FiO2, ratio of the partial pressure of oxygen in arterial blood to the inspired oxygen fraction.
Table 2. Clinical characteristics of PICU patients with LRTIs and of PICU controls whose samples tested positive for HBoV, KIPyV, or 
WUPyV infections, the Netherlands, 2005–2008* 
Patient
no. Diagnosis
Virus
(Ct value) 
Sample
type  Sex 
Age,
mo Immunocompromised
Other underlying 
disease
Length of 
stay, d 
Other
viruses 
LRTI group 
  1  LRTI HBoV (39.4)  NPA F 13 No Pulmonary dysplasia 
(home mechanical 
ventilation)
10 Adeno,
hMPV
 2  LRTI HBoV  (15.0)  NPA F 9 No IRDS,  PVL  10 Adeno
 3  LRTI HBoV  (16.6)  NPA M 13 No Recurrent  wheezing  5 RSV
 4  LRTI HBoV  (15.0)  NPA F 19 No IRDS 7 None
 5  LRTI WUPyV  (19.6) NPA M 1 No None 11 RSV
 6  LRTI WUPyV  (34.1) NPA F 41 No Mitochondrial
encephalopathy 
18 Influenza
Control group 
 7  Sepsis HBoV  (36.5)  NPA F 27 No None 7 NA
 8  Infectious
meningitis
HBoV (34.7)  NPA F 100 No 22Q11 deletion 
(cardiac and 
neurologic disease) 
3N A
  9  URTI HBoV (37.9)  NPA M 41 No Spinal muscular 
atrophy 
74 NA
 10  Observation
after brain 
biopsy 
HBoV/ KIPyV 
(32/39)
NPA F 127 Yes AML,  BMT, 
Brochiolitis obliterans 
46 NA
  11  VSD closure  WUPyV (33.8)  Throat
swab 
F 15 No VSD 2 NA
  12  Septic shock  WUPyV (34.4)  NPA M 40 No None 19 NA
 13  Cardiac
malformation
KIPyV (34.1)  NPA F 4 No Cardiac malformation  14 NA
  14  Septic shock  KIPyV (23.1)  NPA M 152 Yes  AML, aplasia  11 NA
 15  ALTE KIPyV  (26.7)  NPA M 2 No None 8 NA
*PICU, Pediatric Intensive Care Unit, Wilhelmina Children’s Hospital, University Medical Center Utrecht, the Netherlands; LRTI, lower respiratory tract 
infection; HBoV, human bocavirus; KIPyV, KI polyomavirus; WUPyV, WU polyomavirus; Ct, cycle threshold; NPA, nasopharyngeal aspirate; Adeno, 
adenovirus; hMPV, human metapneumovirus; RSV, respiratory syncytial virus; IRDS, idiopathic respiratory distress syndrome; PVL, periventricular 
leukomalacia; NA, not assessed; URTI, upper respiratory tract infection; AML, acute myeloid leukemia; BMT, bone marrow transplant; VSD, ventricular 
septal defect; ALTE, apparent life-threatening event. 19 months of age with a severe LRTI. Bacterial throat and 
blood cultures remained negative.
In the control group, HBoV was found in samples 
from 4 (4.8%) patients, KIPyV was found in 4 (4.8%), 
and WUPyV was present in 2 (2.4%) samples from the 83 
patients whose samples could be tested. One patient was 
found to have a co-infection with HBoV and KIPyV.
Median Ct values for HBoV, KIPyV, and WUPyV 
combined were 18.1 (interquartile range [IQR] 20.4) for 
the LRTI group and 34.4 (IQR 5.1) for the control group 
(p = 0.09; Figure). The Ct values indicate that, on average, 
the viral load in the LRTI group might be higher than in the 
control group.
Conclusions
In the present study, the prevalences of HBoV, KIPyV, 
and WUPyV in PICU patients with LRTI (n = 78) or with-
out LRTI (n = 83) were similar (5.1%, 0%, 2.6%; and 4.8%, 
4.8%, 2.4%, respectively). Most HBoV- and KIPyW-posi-
tive LRTI patients were co-infected with other viruses. One 
LRTI patient with a HBoV single infection was identiﬁ  ed. 
In this patient, HBoV was present in a high quantity. 
Two limitations of our study deserve further discus-
sion. First, LRTI patients were younger than controls 
(LRTI, 100% <5 years; controls, 40% >5 years). How-
ever, the positivity rates for HBoV, KIPyV, and WUPyV 
in control children <5 years were similar to rates of con-
trol children >5 years of age (6/49 vs. 3/34, respectively). 
Hence, the inﬂ  uence of this limitation is likely minor. 
Studies have also shown that the highest incidence of KIP-
yV/WUPyV infection occurs in children ≈1 year of age, 
slightly older than the children in our LRTI group (13–
15). The young age of the LRTI group may have resulted 
in a lower than expected positivity rate for this group. 
Second, all LRTI patients had nasopharyngeal aspirates 
taken; however, 68.7% of controls had provided nasopha-
ryngeal aspirates. HBoV and KIPyV/WUPyV infections 
were more common in controls who had nasopharyngeal 
aspirate samples taken than in those who had throat swab 
samples taken (8/57 vs. 1/26). This difference in positiv-
ity for nasopharyngeal aspirates strengthens our conclu-
sion that these viruses are not found more frequently in 
PICU children with LRTI.
Sampling errors make precise quantiﬁ  cation of viral 
loads difﬁ  cult. Nevertheless, in the LRTI group, low Ct 
values, which indicate high viral loads, were found in na-
sopharyngeal samples taken from 3 patients infected with 
HBoV (Ct ≈ 15) and from 1 patient infected with WUPyV 
(Ct = 19). Ct values found in nasopharyngeal samples from 
patients in the control group were much higher, 32–39. A 
possible explanation for this difference is that high viral 
loads in the young LRTI population represent symptomatic 
primary infection, whereas the low viral load in the older 
controls might represent asymptomatic long-term shedding. 
Further studies are needed to show the clinical implications 
of infections with these viruses.
Prevalences of HBoV, KIPyV, and WUPyV infections 
in children in the PICU is low (≈<5% for LRTI patients and 
controls), and these agents are unlikely to be a major cause 
of LRTI at the PICU. However, HBoV might be pathogen-
ic in some PICU patients because 1 person with a HBoV 
single infection in a high quantity was identiﬁ  ed. Further 
studies using quantitative viral detection are needed to in-
vestigate the probability that HBoV, KIPyV, and WUPyV 
represent etiologic agents of LRTI. 
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